Indeed, near 90% of HNSCC show over-expression of EGFR, in association with a more aggressive disease and lower survival rate; therefore, Cetuximab (marketed as Erbitux®) has entered the routine therapeutic protocols in association with CT and RT for patients with locally advanced and recurrent metastatic disease (3, 8). Here, EGFR is linked to head and neck squamous cell carcinoma.